Atrium Therapeutics Q3 2026 net loss widens to $4.27 million
RNA•Atrium Therapeutics’ third-quarter 2026 net loss widened to $4.27 million, while collaboration revenue rose 24% year over year to $15.32 million, primarily from a Bristol Myers Squibb milestone. The company reported $232.1 million in cash, cash equivalents and short-term investments at September 30, with anticipated cash runway through 2028.
1. Quarterly results
Atrium Therapeutics reported a third-quarter 2026 net loss of $4.27 million, wider than a year earlier. Collaboration revenue rose 24% year over year to $15.32 million, primarily related to a Bristol Myers Squibb milestone, while operating expenses climbed 75% to $21.95 million.
2. Trial and cash update
The first patient was dosed in Corventis, the ATR 1072 Phase 1/2 trial, and initial proof-of-concept data are expected in the second half of 2027. Cash, cash equivalents and short-term investments totaled $232.1 million at September 30; the company anticipates its cash runway will extend through 2028.
